Clinical Trials
158 trialsSafety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
Tactical Therapeutics, Inc.
TTField in Combination With Temozolomide and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma.
Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
Sintilimab in Combination With Bevacizumab and Temozolomide in Recurrent Glioblastoma (GBM) Patients
Zhujiang Hospital
GLIOSTAR
Philogen S.p.A.
DEN-STEM
Oslo University Hospital
ISM-GBM
Oslo University Hospital
BORTEM-17
Haukeland University Hospital
Efficacy and Safety of TMZ Plus 6-MP in the Patients With Recurrent Glioblastoma
The First Affiliated Hospital with Nanjing Medical University
Acetyl-Amantadine as a Biomarker in Patients With Glioblastoma
CancerCare Manitoba
The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma
Shanghai Simnova Biotechnology Co.,Ltd.
Ga-68 Prostate Specific Membrane Antigen PET/CT in Gliomas
All India Institute of Medical Sciences, Bhubaneswar
POBIG
The Christie NHS Foundation Trust
ImPRESS
Oslo University Hospital
A Study to Evaluate the Safety, Tolerance and Initial Efficacy of EGFRvIII CAR-T on Glioblastoma
Beijing Tsinghua Chang Gung Hospital
MIRROR
University Medical Center Groningen
TaRRGET
Prof. Franciszek Lukaszczyk Memorial Oncology Center
GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients
Genexine, Inc.
OptimalTTF-2
University of Aarhus
MRSI to Predict Response to RT/TMZ ± Belinostat in GBM
Emory University
Efficacy and Safety of SCAI of Bevacizumab Combined With IC of Tislelizumab in the Treatment of Recurrent Glioblastoma.
Second Affiliated Hospital of Nanchang University
FKBP51s: a New Molecular Biomarker for Glioblastoma? Pre- and Post-operative Blood Levels Evaluation of FKBP51s Protein and Correlation With MRI Phenotype
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
2253
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
RE-GEND
Kyorin University
Treatment of Recurrent Glioblastoma With Fractionated Radiotherapy Combined With Cadonilimab
Second Affiliated Hospital, School of Medicine, Zhejiang University
Study of CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent Glioblastoma
OX2 Therapeutics
Neoadjuvant Chemoimmunotherapy in Recurrent Glioblastoma
University of Louisville
B7-H3 CAR-T for Recurrent or Refractory Glioblastoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Pilot Study of B7-H3 CAR-T in Treating Patients With Recurrent and Refractory Glioblastoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
LITT Combined With Early Use of Temozolomide for Recurrent Glioblastomas
Beijing Tiantan Hospital
A Phase III Study of Postoperative Early Temozolomide Treatment Plus STUPP Regimen for Newly Diagnosed GBM Multiforme
Sun Yat-sen University
Safety and Efficacy of TRPP Therapy in Glioblastoma Multiforme
The Second Hospital of Hebei Medical University
VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma
Vaximm GmbH
A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma
ImmVira Pharma Co. Ltd
Personalized Trial in ctDNA-level-relapse Glioblastoma
Henan Provincial People's Hospital
GBM
Zhongnan Hospital
TTAC-0001 and Pembrolizumab Combination phase1b Trial in Recurrent Glioblastoma
PharmAbcine
Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma Multiforme
Global Neurosciences Institute
Phase 2 Study of CAN008 in Subjects With GBM
CANbridge Life Sciences Ltd.
PLANET
Centre Leon Berard
HIT-HGG-2013
University of Göttingen
FUTURE-GB
University of Oxford
GBM
Northwest Biotherapeutics
The Safety Study of Autologous TILs Therapy for Patients With Glioblastoma Multiforme.
Hebei Senlang Biotechnology Inc., Ltd.
SonoFIRST
Assistance Publique - Hôpitaux de Paris
Irinotecan And Bevacizumab Combined With Re-radiotherapy in Recurrent Glioblastoma
Ruijin Hospital
Neoadjuvant PD-1 Antibody Alone or Combined With DC Vaccines for Recurrent Glioblastoma
Huashan Hospital
CSREIG
Beijing Tiantan Hospital
NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors
Fudan University
Nk Cell Therapy for Recurrent Glioblastoma Multiform Patients
Royan Institute
A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme
Accendatech USA Inc.